Abstract
We reported previously that geniposide showed neurotrophic and neuroprotective activities with the activation of glucagons-like peptide 1 receptor (GLP-1R) in neurons. The current study was designed to further investigate the protective effect of geniposide on β-amyloid (Aβ)-induced cytotoxicity. Our results showed that pre-incubation with geniposide prevented Aβ1-42-induced cell injury in primary cultured cortical neurons. Geniposide also induced the expression of insulin-degrading enzyme (IDE), a major degrading protease of Aβ, in a dose-dependent manner. Moreover, bacitracin, an inhibitor of IDE, and RNAi on Glp-1r gene decreased the neuroprotection of geniposide in Aβ1-42-treated cortical neurons. Our findings indicated that geniposide activating GLP-1R to against Aβ-induced neurotoxicity involved in its regulation on the expression of IDE in cortical neurons, which provided an additional mechanistic insight into the role of GLP-1R in neuroprotection.
Keywords: Alzheimer’s disease (AD), β-amyloid (Aβ), glucagon-like peptide 1 receptor (GLP-1R), insulin-degrading enzyme (IDE), neuroprotection, neurotoxicity, cortical neurons, protease, endogenous, horseradish peroxidase.
CNS & Neurological Disorders - Drug Targets
Title:Geniposide Regulates Insulin-Degrading Enzyme Expression to Inhibit the Cytotoxicity of Aβ1-42 in Cortical Neurons
Volume: 11 Issue: 8
Author(s): Fei Yin, Yonglan Zhang, Lixia Guo, Shuzhen Kong and Jianhui Liu
Affiliation:
Keywords: Alzheimer’s disease (AD), β-amyloid (Aβ), glucagon-like peptide 1 receptor (GLP-1R), insulin-degrading enzyme (IDE), neuroprotection, neurotoxicity, cortical neurons, protease, endogenous, horseradish peroxidase.
Abstract: We reported previously that geniposide showed neurotrophic and neuroprotective activities with the activation of glucagons-like peptide 1 receptor (GLP-1R) in neurons. The current study was designed to further investigate the protective effect of geniposide on β-amyloid (Aβ)-induced cytotoxicity. Our results showed that pre-incubation with geniposide prevented Aβ1-42-induced cell injury in primary cultured cortical neurons. Geniposide also induced the expression of insulin-degrading enzyme (IDE), a major degrading protease of Aβ, in a dose-dependent manner. Moreover, bacitracin, an inhibitor of IDE, and RNAi on Glp-1r gene decreased the neuroprotection of geniposide in Aβ1-42-treated cortical neurons. Our findings indicated that geniposide activating GLP-1R to against Aβ-induced neurotoxicity involved in its regulation on the expression of IDE in cortical neurons, which provided an additional mechanistic insight into the role of GLP-1R in neuroprotection.
Export Options
About this article
Cite this article as:
Yin Fei, Zhang Yonglan, Guo Lixia, Kong Shuzhen and Liu Jianhui, Geniposide Regulates Insulin-Degrading Enzyme Expression to Inhibit the Cytotoxicity of Aβ1-42 in Cortical Neurons, CNS & Neurological Disorders - Drug Targets 2012; 11 (8) . https://dx.doi.org/10.2174/1871527311211080015
DOI https://dx.doi.org/10.2174/1871527311211080015 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coreceptor Switch in Infection of Nonhuman Primates
Current HIV Research Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Structural Biology of the Cell Adhesion Protein CD2: From Molecular Recognition to Protein Folding and Design
Current Protein & Peptide Science Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Bioluminescence Imaging of Pancreatic Islet Transplants
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Complications of Diabetes: An Insight into Genetic Polymorphism and Role of Insulin
Recent Patents on Inflammation & Allergy Drug Discovery Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer
Current Medicinal Chemistry Cardioprotective Utility of Urocortin in Myocardial Ischemia- Reperfusion Injury: Where do We Stand?
Current Molecular Pharmacology Nanomedicine Against Malaria
Current Medicinal Chemistry Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design The Association between Dyslipidemia and Preterm Birth: A Prospective Cohort Study in The North of Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Editorial (Thematic Issue: Endothelial Dysfunction: Treatment with Thiols)
Current Medicinal Chemistry Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery
Current Topics in Medicinal Chemistry Biomechanical Stress-induced Signaling in Smooth Muscle Cells: An Update
Current Vascular Pharmacology New Methods of Affinity Electrophoresis
Current Analytical Chemistry microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Is There a Role for Oral Anticoagulant Therapy in Patients with Peripheral Arterial Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders